Published in Urology on June 01, 1996
Endoscopic management of upper tract transitional cell carcinoma. Indian J Urol (2010) 0.82
Conservative management of upper tract transitional cell carcinoma. Indian J Urol (2008) 0.78
Comprehensive management of upper tract urothelial carcinoma. Adv Urol (2008) 0.78
Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma. Can Urol Assoc J (2013) 0.77
Endourologic management of upper tract transitional cell carcinoma following cystectomy and urinary diversion. Adv Urol (2008) 0.77
Review of topical treatment of upper tract urothelial carcinoma. Adv Urol (2008) 0.77
Early repeated ureteroscopy within 6-8 weeks after a primary endoscopic treatment in patients with upper tract urothelial cell carcinoma: preliminary findings. World J Urol (2015) 0.76
Intracavitary immunotherapy and chemotherapy for upper urinary tract cancer: current evidence. Rev Urol (2013) 0.76
Nephron-sparing Management of Upper Tract Urothelial Carcinoma. Rev Urol (2014) 0.75
Mitomycin C instillation following ureterorenoscopic laser ablation of upper urinary tract carcinoma. Urol Ann (2013) 0.75
Ureteroscopic management of upper urinary tract urothelial malignancies. Rev Urol (2000) 0.75
MR urography for suspected upper tract urothelial carcinoma. Eur Radiol (2008) 0.75
Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst (2000) 6.77
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc (1988) 6.41
A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology (2001) 5.16
Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int (2006) 4.59
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc (2000) 4.45
Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer (1997) 3.85
Ureteral Stones Clinical Guidelines Panel summary report on the management of ureteral calculi. The American Urological Association. J Urol (1997) 3.55
Comparison of self-reported and medical record health care utilization measures. J Clin Epidemiol (1996) 3.47
Renal cell carcinoma: long-term survival and late recurrence. J Urol (1981) 3.09
Software for optimal matching in observational studies. Epidemiology (1996) 2.84
Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA (1995) 2.70
Comparison of screening methods in the detection of bladder cancer. J Urol (1999) 2.67
Screening for lung cancer. A critique of the Mayo Lung Project. Cancer (1991) 2.47
Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab (1988) 2.20
Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int (2003) 2.17
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol (2001) 2.15
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol (1998) 2.14
Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol (1997) 2.12
A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med (1994) 2.11
Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol (1994) 2.10
Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery (1992) 2.06
Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc (1991) 2.04
Percutaneous removal of kidney stones: review of 1,000 cases. J Urol (1985) 2.04
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol (1996) 2.04
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc (2001) 1.91
Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck (1994) 1.89
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol (2000) 1.89
Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int (2006) 1.86
Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution. J Clin Oncol (1994) 1.75
Prognosis of patients with unilateral renal agenesis. Pediatr Nephrol (1992) 1.74
The periurethral glands do not significantly influence the serum prostate specific antigen concentration. J Urol (1996) 1.73
Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol (1994) 1.73
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol (2001) 1.72
Pediatric reference intervals for 19 biologic variables in healthy children. Mayo Clin Proc (1990) 1.71
Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab (1995) 1.71
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology (1993) 1.67
Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology (1991) 1.65
The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA (1996) 1.65
A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol (2001) 1.64
Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis (1998) 1.64
Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet (1998) 1.63
Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol (1999) 1.61
Incidence rates of stroke in the eighties: the end of the decline in stroke? Stroke (1989) 1.59
Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer (2001) 1.58
The subsequent risk of internal cancer with Bowen's disease. A population-based study. JAMA (1991) 1.58
Correlation of back extensor strength with thoracic kyphosis and lumbar lordosis in estrogen-deficient women. Am J Phys Med Rehabil (1996) 1.58
1999 American Urological Association Gallup Survey: changes in physician practice patterns, treatment of incontinence and bladder cancer, and impact of managed care. J Urol (2000) 1.56
The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA (1993) 1.56
Ureteroscopy: current practice and long-term complications. J Urol (1997) 1.56
Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. J Urol (1989) 1.55
Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology (1993) 1.50
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology (1997) 1.50
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol (1996) 1.47
Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol (1998) 1.46
Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis (1993) 1.45
Chondrosarcoma of the chest wall: factors affecting survival. Ann Thorac Surg (1985) 1.45
Clinical importance of microhematuria. JAMA (1979) 1.45
Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol (2000) 1.45
Leiomyoma of the bladder. J Urol (1986) 1.42
Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc (1998) 1.42
Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology (1998) 1.41
Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg (1984) 1.41
A prospective randomized comparison of epidural infusion of fentanyl and intravenous administration of morphine by patient-controlled analgesia after radical retropubic prostatectomy. Mayo Clin Proc (1992) 1.40
Current evaluation and management of renal and ureteral stones. Saudi Med J (2001) 1.40
Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results. Mayo Clin Proc (1995) 1.40
Incidence, clinical features, and prognosis in Bell's palsy, Rochester, Minnesota, 1968-1982. Ann Neurol (1986) 1.39
Transurethral microwave thermotherapy for prostatism: early Mayo Foundation experience. Mayo Clin Proc (1992) 1.39
Retroperitoneal approach for aortic surgery: is it worth it? Cardiovasc Surg (2001) 1.39
Transfrontal orbital decompression after failure of transantral decompression in optic neuropathy of Graves' disease. Mayo Clin Proc (1993) 1.39
Physical activity, but not aerobic capacity, correlates with back strength in healthy premenopausal women from 29 to 40 years of age. Mayo Clin Proc (1993) 1.38
Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma. Surgery (1991) 1.38
Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer (1987) 1.37
The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis (1988) 1.36
Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N Engl J Med (1994) 1.36
Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery (1998) 1.35
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2000) 1.32
Surgeon's role in the management of solitary renal cell carcinoma metastases occurring subsequent to initial curative nephrectomy: an institutional review. Ann Surg Oncol (1994) 1.31
Percutaneous antegrade endopyelotomy: review of 50 consecutive cases. J Urol (1995) 1.27